연구성과로 돌아가기
2024 연구성과별 연구자 정보 (1473 / 2344)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Qin, Shukui | Qin, S | 4 | Jinling Hosp, Canc Ctr Nanjing, Nanjing, Peoples R China | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Ren, Zhenggang | Ren, Z | 5 | Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Hepat Oncol, Shanghai, Peoples R China | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Chan, Stephen | Chan, S | 6 | Chinese Univ Hong Kong, State Key Lab Translat Oncol, Dept Clin Oncol, Sir Yue Kong Pao Ctr Canc, Hong Kong, Peoples R China | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Arai, Yasuaki | Arai, Y | 7 | Natl Canc Ctr, Dept Diagnost Radiol, Chuo Ku, Tokyo, Japan | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Heo, Jeong | Heo, J | 8 | Pusan Natl Univ, Dept Internal Med, Coll Med, Pusan, South Korea | Q-1055-2018 | Lee, Jeong-Hoon | bsangro@unav.es; | |||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Heo, Jeong | Heo, J | 8 | Pusan Natl Univ Hosp, Biomed Res Inst, Pusan, South Korea | Q-1055-2018 | Lee, Jeong-Hoon | bsangro@unav.es; | |||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Mai, Ahn | Mai, A | 9 | Nhan Dan Gia Dinh Hosp, Dept Gen Surg, Ho Chi Minh City, Vietnam | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Escobar, Jose | Escobar, J | 10 | Hosp San Lucas Cardiolog Sureste, Chiapas, Mexico | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Chuken, Yamil Alonso Lopez | Chuken, YAL | 11 | I Can Oncol Ctr, New Leon, Mexico | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Yoon, Jung-Hwan | Yoon, JH | 12 | Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Yoon, Jung-Hwan | Yoon, JH | 12 | Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul, South Korea | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Tak, Won Young | Tak, WY | 13 | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Suttichaimongkol, Tanita | Suttichaimongkol, T | 14 | Khon Kaen Univ, Dept Med, Div Gastroenterol & Hepatol, Fac Med, Khon Kaen, Thailand | JDW-6886-2023 | Suttichaimongkol, Tanita | bsangro@unav.es; | |||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Bouattour, Mohamed | Bouattour, M | 15 | Hop Beaujon, AP HP, Med Oncol, Paris, France | bsangro@unav.es; | |||||
| mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma | Lin, Shi-Ming | Lin, SM | 16 | Chang Gung Mem Hosp, Linkou Med Ctr, Dept Internal Med, Taoyuan, Taiwan | NPI-5122-2025 | Lin, Shiming | bsangro@unav.es; |
페이지 이동: